Bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disea… Read more
Bluebird bio Inc (BLUE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: 0.751x
Based on the latest financial reports, Bluebird bio Inc (BLUE) has a cash flow conversion efficiency ratio of 0.751x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.44 Million) by net assets ($-57.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bluebird bio Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Bluebird bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bluebird bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bluebird bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BUUU Group Limited Class A Ordinary Share
NASDAQ:BUUU
|
N/A |
|
Thai Nguyen International Hospital JSC
VN:TNH
|
0.051x |
|
Yeo Teknoloji Enerji ve Endustri AS
IS:YEOTK
|
-0.363x |
|
IZEA Inc
NASDAQ:IZEA
|
0.024x |
|
Indian Hume Pipe Company Limited
NSE:INDIANHUME
|
-0.005x |
|
Wallbridge Mining Company Limited
OTCQB:WLBMF
|
-0.002x |
|
Prevas AB
ST:PREV-B
|
0.058x |
|
New Horizon Aircraft Ltd
NASDAQ:HOVR
|
-0.180x |
Annual Cash Flow Conversion Efficiency for Bluebird bio Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Bluebird bio Inc from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-31.53 Million | $-260.02 Million | 8.246x | +782.46% |
| 2023-12-31 | $194.54 Million | $-235.05 Million | -1.208x | +32.79% |
| 2022-12-31 | $196.34 Million | $-352.95 Million | -1.798x | -5.85% |
| 2021-12-31 | $374.28 Million | $-635.64 Million | -1.698x | -389.27% |
| 2020-12-31 | $1.36 Billion | $-470.35 Million | -0.347x | +20.97% |
| 2019-12-31 | $1.28 Billion | $-564.38 Million | -0.439x | -100.26% |
| 2018-12-31 | $1.89 Billion | $-413.43 Million | -0.219x | -26.91% |
| 2017-12-31 | $1.62 Billion | $-280.55 Million | -0.173x | +20.77% |
| 2016-12-31 | $869.44 Million | $-189.65 Million | -0.218x | -88.48% |
| 2015-12-31 | $850.50 Million | $-98.43 Million | -0.116x | +4.76% |
| 2014-12-31 | $491.26 Million | $-59.69 Million | -0.122x | -142.41% |
| 2013-12-31 | $151.67 Million | $43.45 Million | 0.286x | -24.11% |
| 2012-12-31 | $-55.75 Million | $-21.04 Million | 0.377x | +72.13% |
| 2011-12-31 | $-55.71 Million | $-12.22 Million | 0.219x | -- |